Tirzepatide in Hispanic/Latino Patients with Type 2 Diabetes: A Subgroup Analysis of the SURPASS program.

Juan Pablo FríasRodolfo J GalindoHui WangRaleigh E MalikK Karthik ChivukulaJuan M Maldonado

Published in: The Journal of clinical endocrinology and metabolism (2023)

Tirzepatide significatively reduced HbA1c and body weight in Hispanic/Latino and non-Hispanic/Latino patients. Tirzepatide was generally well tolerated in both subgroups. Efficacy and safety trends were comparable between subgroups and with the overall trial populations.

Keyphrases

african american
body weight
newly diagnosed
ejection fraction
phase iii
clinical trial
study protocol
randomized controlled trial
patient reported outcomes
phase ii
open label